Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | WNT1 | P04628 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31719948 | 0.85 | CA12 (0.36) | SMN1; SMN2PARP1 | |
| SCHEMBL31719950 | 0.82 | ALDH1A1 (0.36) | JAK3SMN1; SMN2KMT2ALMNA | |
| SCHEMBL30228247 | 0.81 | CA12 (0.41) | SMN1; SMN2KMT2ALMNA | |
| SCHEMBL30283336 | 0.71 | ROCK1 (0.39) | PARP1 | |
| SCHEMBL30283623 | 0.70 | ROCK1 (0.39) | JAK3LMNAPARP1 | |
| SCHEMBL31719833 | 0.69 | ROCK1 (0.34) | JAK3KMT2A | |
| SCHEMBL31719957 | 0.69 | ROCK1 (0.34) | JAK3KMT2A | |
| SCHEMBL31719858 | 0.69 | ROCK1 (0.34) | JAK3KMT2A | |
| SCHEMBL30283587 | 0.68 | ALDH1A1 (0.41) | SMN1; SMN2KMT2ALMNAOPRM1 | |
| SCHEMBL30283672 | 0.68 | ALDH1A1 (0.42) | SMN1; SMN2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | POLRMT, TFAM, UQCRC1 | PTGER3 4199/4885JAK3 4329/4885SMN1; SMN2 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.